A multicentre, double blind, randomized, parallel group, Phase 3 safety extension study to evaulate the safety and tolerability of Benralizumab (MEDI-563) in asthmatic adults and adolescents on inhaled corticosteroid plus long-acting p2 agonist (BORA)